Sotuletinib (BLZ945)
Sotuletinib (BLZ945)
ChemLeader
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
5 mg 10 mg 25 mg
Product Availability
3-5days
Price
$150.00
Member price
Product Availability
3-5days
Price
$225.00
Member price
Product Availability
3-5days
Price
$400.00
Member price
Quantity
- +
Product Overview
Product Name Sotuletinib (BLZ945)
CAS953769-46-5
FormulaC20H22N4O3S
MW398.48
AppearanceOff-white to light brown powder
Storage conditionDry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
Security information
Product details

Sotuletinib (formerly BLZ945; BLZ-945) is a novel, potent, selective, orally bioactive, and brain-penetrant CSF-1R (colony stimulating factor 1 receptor) inhibitor with potential antitumor activity. It exhibits 1000-fold higher selectivity against its closest receptor tyrosine kinase homologs and inhibits CSF-1R with an IC50 of 1 nM. Glioma-bearing mice demonstrate high in vivo antitumor efficaciousness of BLZ945. Sotuletinib was designated as an orphan drug by the US FDA in August 2022 in order to treat patients suffering from Amyotrophic Lateral Sclerosis (ALS), a progressive neurological disorder that affects nerve cells in the brain and spinal cord and results in loss of motor control.

Related literature
Related
Sorry, no related items
History
Urelumab (Anti-TNFRSF9 / 4-1BB / CD137)
Sotuletinib (BLZ945)
Laduviglusib dihydrochloride | CHIR-99021 dihydrochloride | CT99021 dihydrochloride
Alexa fluor 647 NHS ester
trans-Doxercalciferol